Skip to main content

MediConsult Capital

India's Medtech Scale-Up Needs a Different Kind of Capital

Blog

For most of the last decade, India’s medical devices story was told through its import bill. That story is changing. MRI scanners, CT systems, linear accelerators, heart valves and stents are now being made in India, and Indian devices reach more than 180 countries.

Scale brings a new question. The capital that built India’s first generation of medtech manufacturers was largely promoter money, bank lines and early-stage venture funding. The next phase needs something different: longer-dated capital for R&D and clinical evidence, structured debt for plants and equipment, and strategic M&A to reach global scale.

This article looks at where India’s medical devices market stands, what policy has de-risked, where capital is flowing, and how companies can finance the next leg of growth.

How big is India’s medical devices market?

India’s medical devices market was valued at about $15.2 billion in 2025 and is projected to reach $50.1 billion by 2030. That makes India the fourth-largest medtech market in Asia and one of the top 20 globally. The government aims to lift India’s share of the global market from about 1.6% to nearly 12%.

Demand is broad-based. Rising incomes, wider health insurance cover, new hospital capacity and medical tourism are pulling up demand for both affordable mass-use devices and advanced specialty equipment.

From importer to exporter

Exports are where the shift is most visible. Medical device exports reached ₹33,909 crore (about $4 billion) in FY25, up 88% since FY19. Consumables make up nearly half of exports, reflecting India’s strength in cost-efficient, high-volume manufacturing.

The gap is at the top end. Imports touched $8.6 billion in FY25, and electro-medical equipment accounts for nearly 60% of them. Closing this gap is the single largest opportunity in Indian medtech, and also the most capital-intensive.

How has policy de-risked medtech investment in India?

Three schemes now carry part of the capital burden that once sat entirely with promoters.

Scheme

Outlay

Progress so far

PLI for Medical Devices

₹3,420 crore, 5% incentive on incremental sales

27 projects approved (14 MSMEs); ₹1,153 crore actual investment; ₹266.64 crore incentives released up to FY25

Medical Device Parks

Common testing and infrastructure in Noida, Ujjain and Kancheepuram

210 manufacturing units allotted plots across the three parks

Scheme for Strengthening Medical Device Industry

₹500 crore

Support for clusters, components, clinical studies and skills

The PLI scheme has done what it was designed to do. Approved projects now manufacture MRI and CT equipment, LINACs, mammography systems, C-arms, heart valves, stents and dialysis products in India. Medical device FDI is also open at 100% under the automatic route.

What happens after the PLI scheme ends?

The PLI performance period closes in FY2026–27. For investors and lenders, the question shifts from “Is there policy support?” to “Do margins hold without it?” Companies that can show sustainable unit economics, export traction and regulatory readiness without incentives will command better valuations and better debt terms.

Where is capital flowing in Indian medtech?

Four areas stand out for investors and strategic buyers over the next three to four years.

Segment

Why capital is interested

What it needs

Imaging and radiology

Largest import category; PLI has already seeded local production

Long-gestation equity, equipment and project finance

Implants and cardiac devices

High value per unit; local makers of valves and stents are scaling

Clinical evidence funding, capacity expansion capital

Components and sub-assemblies

Sensors, precision parts, medical plastics and electronics are the next localisation frontier

Capex debt, cluster-linked financing

Contract manufacturing and OEM partnerships

Global OEMs are diversifying supply chains towards India

Growth equity, JV structuring, cross-border M&A

The common thread: the next wave of value sits in higher-technology, higher-capex segments. These businesses take longer to reach cash breakeven, which changes how they should be financed.

How should medical device companies finance the next growth phase?

There is no single right instrument. The right capital structure depends on where a company sits on its growth curve, and most scaling medtech businesses will use more than one.

1. Growth equity for R&D and clinical evidence

High-end devices need years of development, testing and regulatory approval before revenue scales. Private equity and growth capital fit this phase best. The key is sizing rounds to milestones, so founders raise at higher valuations as evidence builds rather than diluting heavily upfront.

2. Structured debt for plants and equipment

Manufacturing capacity, testing infrastructure and equipment are well suited to debt. Project finance, term loans and equipment finance preserve equity for higher-risk work. Companies with PLI approvals or device-park allotments are often better placed to secure bank funding, as long as cash flows hold up beyond the incentive period.

3. Hybrid structures that bridge the two

Many mid-sized manufacturers fall between venture-stage and bank-ready. Blended structures, such as equity with a debt tranche or convertible instruments, can extend runway without excessive dilution.

4. M&A, joint ventures and strategic partnerships

Consolidation is already underway across Indian healthcare. MediConsult Capital’s India Healthcare M&A Tracker for Q2 2026 recorded ₹1,23,960 crore of disclosed deal value. It also found six outbound acquisitions by Indian healthcare and health-tech companies into the US and Europe in a single quarter.

For medtech, this points to three likely moves:

  • Mid-sized device makers combining to reach the scale global buyers expect
  • Global OEMs acquiring or partnering with Indian manufacturers for supply-chain depth
  • Indian companies buying technology, distribution or regulatory access abroad

Each of these needs careful valuation, deal structuring and execution, often across borders.

The road ahead

India’s medical devices sector has proven it can manufacture at scale. The next phase is about proving it can build globally competitive, technology-led businesses, and that depends as much on how companies are financed as on what they make.

The companies that pull ahead will match the right capital to each stage of growth, prepare early for life after incentives, and treat partnerships and M&A as growth levers rather than exits.

At MediConsult Capital, we offer Comprehensive Financial Advisory & Capital Solutions for the Indian & Global Life Sciences sector, across M&A, private equity, debt syndication and commercial excellence for OEMs. If you are planning your next growth phase, let’s connect.